Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Assets (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Assets for 14 consecutive years, with $108.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets fell 34.06% year-over-year to $108.4 million, compared with a TTM value of $108.4 million through Dec 2025, down 34.06%, and an annual FY2025 reading of $108.4 million, down 34.06% over the prior year.
  • Assets was $108.4 million for Q4 2025 at Karyopharm Therapeutics, up from $96.2 million in the prior quarter.
  • Across five years, Assets topped out at $358.2 million in Q4 2022 and bottomed at $96.2 million in Q3 2025.
  • Average Assets over 5 years is $230.2 million, with a median of $247.3 million recorded in 2021.
  • The sharpest move saw Assets rose 17.32% in 2022, then tumbled 50.99% in 2025.
  • Year by year, Assets stood at $305.3 million in 2021, then rose by 17.32% to $358.2 million in 2022, then plummeted by 32.87% to $240.4 million in 2023, then crashed by 31.62% to $164.4 million in 2024, then tumbled by 34.06% to $108.4 million in 2025.
  • Business Quant data shows Assets for KPTI at $108.4 million in Q4 2025, $96.2 million in Q3 2025, and $104.9 million in Q2 2025.